REG - Redx Pharma plc - New Grant of Options

Redx PharmaAnnouncement

01/03/2021 10:00

RNS Number : 6793Q
  
Redx Pharma plc
  
01 March 2021
  
 

REDX PHARMA PLC
("Redx" or "the Company" or "Redx Pharma")
 
New Grant of Options
 
Alderley Park, 1 March 2021 Redx Pharma (AIM:REDX), the drug discovery and development company focused on cancer and fibrosis, announces that further to the announcement made on 27 October 2020, Dr Jane Robertson assumed her new role as Chief Medical Officer on 1 March 2021.  
 
In addition, the Company announces that on 1 March 2021, options over 1,500,000 ordinary shares of 1p each in the share capital of the Company, were granted to Dr Jane Robertson, Chief Medical Officer, under the All employee Share Option scheme, on the following basis:
 
The options were granted at 66p per share, being the closing price on 26 February 2021.
 
 



Name


Position


Number of Options Granted


Vesting Date


Total Options Held Following the Grant




Jane Robertson (PDMR)


Chief Medical Officer


100,000
100,000
100,000
1,200,000


1 March 2022
1 March 2023
1 March 2024
1 March 2024 (subject to performance conditions)


 
 
 
1,500,000

























 
 
Following the grant referred to above, the Company will have granted options over a total of 31,898,764 Ordinary Shares representing 11.6 per cent. of the share capital in issue. The number of options that may be awarded under the Scheme, and all prior share incentive plans, remains limited such that the aggregate number of Ordinary Shares of 1p each under option will be less than 15 per cent. of the total issued share capital of the Company.
 
 



1.


Details of the person discharging managerial responsibilities/person closely associated




a)


 Name


Jane Robertson




2.


Reason for the notification




a)


Position/status


Chief Medical Officer




b)


Initial notification/Amendment


Initial Notification




3.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Redx Pharma Plc




b)


LEI


213800HMS4EBXO589Y37




4.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument


Options over Ordinary Shares of 1p each




b)


Identification code


ISIN: GB00BSNB6S51




c)


Nature of the transactions


Grant of options under the Redx All Employee Share Option Scheme




d)


Price(s) and volume(s)


Price: 66p pence per share
Volume: 1,500,000 shares




e)


Aggregated information
-     Aggregated volume
-     Price


As for d) above




f)


Date of the transactions


1 March 2021




f)


Place of the transactions


Off-market



 
 
 



For further information, please contact:


















Redx Pharma Plc 


T: +44 1625 469 918




Iain Ross, Chairman
Lisa Anson, Chief Executive
James Mead, Chief Financial Officer


















SPARK Advisory Partners (Nominated Adviser)


 T: +44 203 368 3550




Matt Davis/Adam Dawes


















WG Partners LLP (Broker)


T: +44 20 3705 9330




Claes Spång/Chris Lee/David Wilson




























FTI Consulting


T: +44 20 3727 1000




Simon Conway/Ciara Martin








 
 







 
About Redx Pharma Plc 
 
Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx's lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top line data expected in H1 2021 and the Company's selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
 
The Company's  core capability  of converting  medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically validated targets has been recognized by others. Over the last three years the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology (now Eli Lilly).
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHKFLBBFXLZBBQ